Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors — Stella

Home/Solid Tumor, Adult/Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

View on ClinicalTrials.gov

Recruiting

Back to Solid Tumor, Adult trials

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

Key details

Phase

Early testing

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment target

~30 participants

Started

June 2024

Primary completion

December 2029

Age range

18 Years – 75 Years

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.